
Amanda Nerstad/LinkedIn
May 10, 2025, 09:59
Amanda Nerstad Shares Experience as Participant in ALK Vaccine Trial for Lung Cancer
Amanda Nerstad, Lung Cancer Survivor and Advocate, posted on LinkedIn:
“Thank you to Roche for sharing my story — I’m honored to be patient 2 in the ALK vaccine trial. Grateful for the progress in ALK-positive lung cancer.”
Amanda Nerstad expressed appreciation to Roche for amplifying her story as the second participant in the ALK vaccine trial. She highlighted ongoing progress in the treatment of ALK-positive lung cancer and her advocacy as a survivor.
More posts featuring Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 09:47
May 10, 2025, 09:44
May 10, 2025, 09:40
May 10, 2025, 09:20